Marinus Pharmaceuticals, Inc. (MRNS): Price and Financial Metrics

Marinus Pharmaceuticals, Inc. (MRNS): $7.25

0.19 (+2.69%)

POWR Rating

Component Grades








Add MRNS to Watchlist
Sign Up

Industry: Biotech




#189 of 378

in industry

MRNS Price/Volume Stats

Current price $7.25 52-week high $9.82
Prev. close $7.06 52-week low $3.46
Day low $6.96 Volume 1,127,382
Day high $7.51 Avg. volume 566,718
50-day MA $7.74 Dividend yield N/A
200-day MA $6.27 Market Cap 366.47M

MRNS Stock Price Chart Interactive Chart >


  • MRNS scores best on the Momentum dimension, with a Momentum rank ahead of 78.35% of US stocks.
  • MRNS's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • MRNS's current lowest rank is in the Stability metric (where it is better than 5.18% of US stocks).

MRNS Stock Summary

  • With a price/sales ratio of 17.91, MARINUS PHARMACEUTICALS INC has a higher such ratio than 93.74% of stocks in our set.
  • Revenue growth over the past 12 months for MARINUS PHARMACEUTICALS INC comes in at -21.83%, a number that bests only 10.64% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MRNS comes in at -24.07% -- higher than that of only 17.09% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MARINUS PHARMACEUTICALS INC are PXLW, VERU, CDXS, BGRY, and IMGN.
  • Visit MRNS's SEC page to see the company's official filings. To visit the company's web site, go to

MRNS Valuation Summary

  • In comparison to the median Healthcare stock, MRNS's price/earnings ratio is 144.4% lower, now standing at -10.7.
  • MRNS's price/sales ratio has moved NA NA over the prior 107 months.

Below are key valuation metrics over time for MRNS.

Stock Date P/S P/B P/E EV/EBIT
MRNS 2023-05-23 18.1 4.6 -10.7 -18.6
MRNS 2023-05-22 18.1 4.6 -10.7 -18.7
MRNS 2023-05-19 18.9 4.8 -11.2 -19.7
MRNS 2023-05-18 19.0 4.8 -11.3 -19.7
MRNS 2023-05-17 19.4 4.9 -11.5 -20.2
MRNS 2023-05-16 19.9 5.1 -11.8 -20.7

MRNS Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -157.54%.
  • Its year over year net cashflow from operations growth rate is now at -6.2%.
  • Its 4 year price growth rate is now at 30.43%.
Over the past 33 months, MRNS's revenue has gone up $19,836,000.

The table below shows MRNS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 19.836 -112.722 -15.465
2022-06-30 27.61 -77.674 -106.606
2022-03-31 27.725 -66.957 -90.996
2021-12-31 15.345 -55.477 -98.776
2021-09-30 15.372 -50.125 -87.94
2021-06-30 5.429 -69.997 -84.092

MRNS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRNS has a Quality Grade of D, ranking ahead of 11.62% of graded US stocks.
  • MRNS's asset turnover comes in at 0 -- ranking 440th of 682 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with MRNS.

The table below shows MRNS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -66.832
2021-03-31 0 NA -93.470
2020-12-31 0 NA -20.937
2020-09-30 0 NA -22.684
2020-06-30 0 NA -28.712
2020-03-31 0 NA -57.851

MRNS Price Target

For more insight on analysts targets of MRNS, see our MRNS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.88 Average Broker Recommendation 1.25 (Strong Buy)

Marinus Pharmaceuticals, Inc. (MRNS) Company Bio

Marinus Pharmaceuticals is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The company was founded in 2003 and is based in Radnor, Pennsylvania.

MRNS Latest News Stream

Event/Time News Detail
Loading, please wait...

MRNS Latest Social Stream

Loading social stream, please wait...

View Full MRNS Social Stream

Latest MRNS News From Around the Web

Below are the latest news stories about MARINUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MRNS as an investment opportunity.

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

RADNOR, Pa., May 17, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

Yahoo | May 17, 2023

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2023 Earnings Call Transcript

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2023 Earnings Call Transcript May 11, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.67, expectations were $-0.72. Operator: Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ […]

Yahoo | May 16, 2023

Analyst Forecasts For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Celebrations may be in order for Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders, with the analysts...

Yahoo | May 16, 2023

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 11, 2023

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

RADNOR, Pa., May 11, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.

Yahoo | May 11, 2023

Read More 'MRNS' Stories Here

MRNS Price Returns

1-mo -20.33%
3-mo 3.28%
6-mo 52.31%
1-year N/A
3-year -28.64%
5-year -71.00%
YTD 82.16%
2022 -66.50%
2021 -2.62%
2020 41.20%
2019 -24.74%
2018 -64.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!